COMMUNIQUÉS West-GlobeNewswire

STRATA Skin Sciences IP Portfolio Holds Exclusivity in Combination Therapies of Its XTRAC Excimer Laser with JAK Inhibitors, Systemic and Biologic Drugs, Bolstering Expansion into New Indications Like Vitiligo and Other Auto-Immune Skin Conditions
02/09/2025
Strata continues to work closely with CMS to ensure a rapid implementation of the extended codes HORSHAM, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a [...]
First US Commercial Robotic HD Mapping Procedures Successfully Completed with MAGiC Sweep Catheter
02/09/2025
ST. LOUIS, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the successful completion of the [...]
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
02/09/2025
Study shows approximately 18% savings per hospitalization DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming [...]
Hydreight Technologies Signs Definitive Agreement to Acquire 5% Equity Stake in Perfect Scripts, LLC, with Option to Increase to 40%, and Establish Strategic Partnership
02/09/2025
Not for distribution to United States newswire services or for dissemination in the United States. VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS)(OTCQB: HYDTF)( [...]
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences
02/09/2025
SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress
02/09/2025
Oral presentation highlighted improvements in heart failure endpoints and major adverse cardiovascular events (MACE) among older adults irrespective of age THE WOODLANDS, Texas, Sept. 02, 2025 (GLOBE NEWSWIRE) -- [...]
Achieve Life Sciences Announces Participation at Upcoming Investor Conferences
02/09/2025
SEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and [...]
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
02/09/2025
PETACH TIKVA, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Dalit Hazan, [...]
Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial
02/09/2025
– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program – – Study explores Alpha DaRT® combined with chemotherapy in patients with newly diagnosed [...]
Autonomix Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
THE WOODLANDS, TX, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how [...]
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference
02/09/2025
MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders [...]
PolarityBio Announces Launch of Expanded Access Treatment Protocol to Provide Continued Access to SkinTE® for Patients with Wagner 1 Diabetic Foot Ulcers
02/09/2025
SALT LAKE CITY, Sept. 02, 2025 (GLOBE NEWSWIRE) -- PolarityBio , a clinical-stage biotechnology company focused on addressing unmet needs in wound healing through innovation in autologous regenerative skin multicellular [...]
BioStem Technologies to Present at Two Upcoming Investor Conferences
02/09/2025
POMPANO BEACH, Fla., Sept. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-derived biologics for [...]
Outlook Therapeutics Requests Type A Meeting with FDA
02/09/2025
ISELIN, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Digital Utilities Ventures Accelerates Global Growth with Breakthrough Clean Water and Sustainable Agriculture Technologies
02/09/2025
Company advancing commercialization with new contracts, installations, and manufacturing expansion Modular technologies designed for recurring revenue and scalable international growth Proven blueprint guiding global [...]
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital
02/09/2025
NRx CEO presented plans for HOPE Therapeutics rollout in September 2025 and establishment of flagship location in Palm Beach, FL during symposium presentation with leadership from Rockefeller Capital and Matthew [...]
Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
02/09/2025
Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS- [...]
Predicine Submits First Module of PMA Application to FDA for PredicineCARE™ as a Companion Diagnostic Assay in Bladder Cancer
02/09/2025
HAYWARD, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Predicine, Inc. , a leading molecular insights company, today announced the submission of the first module of its premarket approval (PMA) application to the U.S. Food [...]
Femasys Closes $8 Million in Financing to Accelerate Commercialization of Fertility and Birth Control Portfolios
02/09/2025
--Existing investors, including Femasys’ largest shareholders, reaffirm confidence in Femasys’ strategy for growth and impact in women’s health-- ATLANTA, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), [...]

Pages